All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @anessabonner on TikTok · 20s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @anessabonner's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Well, I was stupid and I took another ozimpic shot. I have been throwing up since Tuesday.
  2. 0:09Haven't eaten anything since Tuesday. I don't recommend doing it. Even though you want to be
  3. 0:18skinny really bad.

@anessabonner's Ozempic video leaves us with questions

Anessa behind the block

TikTok creator

40.4K viewsWatch on TikTok

Quick answer

The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series. Multi-day emesis without oral intake carries dehydration and electrolyte imbalance risk that warrants clinical evaluation, not self-management. The phrase 'another shot' suggests a pattern of recurrent adverse reactions without provider-guided dose adjustment or medical assessment between episodes.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @anessabonner's Ozempic video leaves us with questions, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@anessabonner's Ozempic video leaves us with questions" from Anessa behind the block. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series.

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic arkansas f sick." In this clip, the useful excerpt is: "Well, I was stupid and I took another ozimpic shot." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Multi-day vomiting without food intake is a medical situation.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator describes persistent vomiting and inability to eat for multiple days following a semaglutide injection, consistent with severe GLP-1-associated gastrointestinal adverse events documented in the STEP trial series. Multi-day emesis without oral intake carries dehydration and electrolyte imbalance risk that warrants clinical evaluation, not self-management. The phrase 'another shot' suggests a pattern of recurrent adverse reactions without provider-guided dose adjustment or medical assessment between episodes.
  • Vomiting is reported in up to 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM), making it the most common reason for dose reduction or discontinuation.
  • Multi-day vomiting without food intake is a medical situation. Dehydration and electrolyte imbalance can develop quickly and may require IV fluids or emergency evaluation.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Vomiting is reported in up to 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM), making it the most common reason for dose reduction or discontinuation.
  • Multi-day vomiting without food intake is a medical situation. Dehydration and electrolyte imbalance can develop quickly and may require IV fluids or emergency evaluation.
  • Slower titration dramatically reduces severe GI side effects. Standard protocols begin at 0.25mg weekly for four weeks before any increase. Rubino et al. (2022, Obesity) confirmed this reduces discontinuation without sacrificing weight outcomes.
  • Restarting semaglutide after stopping, even briefly, typically requires stepping the dose back down. Jumping back to a prior dose after a gap significantly increases GI reaction severity.
  • Sodhi et al. (2023, JAMA Internal Medicine) found GLP-1 receptor agonists associated with higher rates of gastroparesis and bowel obstruction compared to other weight-loss medications, particularly outside supervised clinical settings.
  • Semaglutide sold as Ozempic is FDA-approved for type 2 diabetes management. Wegovy carries the FDA approval for chronic weight management. Using either without a licensed prescriber and proper monitoring removes the safety infrastructure the drug's approval was built around.
  • If you are experiencing severe or prolonged GI side effects on any GLP-1 medication, contact your prescriber before your next injection, not after.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @anessabonner actually say?

She described taking another semaglutide injection, calling herself "stupid" for it, and then experiencing continuous vomiting since Tuesday with no food intake for multiple days. Her closing line was direct: "I don't recommend doing it. Even though you want to be skinny really bad." That's actually a more honest disclosure than most GLP-1 content on this platform. She's describing what sounds like severe gastrointestinal toxicity, not the mild nausea that pharma messaging tends to gloss over. The phrase "another shot" implies she had already reacted badly before and injected again anyway, which is the part worth unpacking clinically.

Does the science back this up?

Yes, and the data is more alarming than most creators acknowledge. Semaglutide's GI side effect profile is well-documented. A 2023 JAMA Internal Medicine study by Sodhi et al. found that GLP-1 receptor agonists were associated with significantly higher risks of pancreatitis, gastroparesis, and bowel obstruction compared to bupropion-naltrexone in patients using these drugs for weight loss. Nausea and vomiting are the most common adverse events across trials, reported in roughly 20-44% of participants in the SUSTAIN and STEP trial series. What she's describing, days of vomiting with zero food intake, sits at the more severe end of that spectrum and borders on what clinicians would flag as dehydration risk requiring evaluation. This is not just "feeling a little queasy."

  • Sodhi et al., 2023, JAMA Internal Medicine: GLP-1 agonists linked to gastroparesis and other serious GI events.
  • STEP 1 trial (Wilding et al., 2021, NEJM): nausea reported in 44% of semaglutide participants.
  • Davies et al., 2021, Diabetes Care: vomiting rates roughly 24% in semaglutide 2.4mg group.

What did they get wrong (or right)?

She got more right than wrong. The experience she described is real, documented, and under-discussed in GLP-1 social media content. Credit where it's due: she didn't romanticize it. However, there are two problems. First, she framed this as a personal choice consequence rather than a medical safety signal. Someone vomiting continuously for multiple days after an injection should contact their prescriber or seek care, not just wait it out. That part was missing. Second, the implicit framing throughout is that the drug's purpose is to "be skinny," which strips away the clinical indication entirely. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management in qualifying patients (Wegovy). Using it without medical supervision, or continuing after severe adverse reactions without consulting a provider, is where the real risk lives. She called herself "stupid," but the problem isn't stupidity. It's lack of clinical oversight.

What should you actually know?

Persistent vomiting after a GLP-1 injection is not something to push through alone. Multi-day vomiting leads to dehydration and electrolyte imbalance, which can become medically serious. If you are on semaglutide or any GLP-1 and experience vomiting lasting more than 24-48 hours, that is a conversation for your prescriber, not a TikTok comment section. Dose titration exists specifically to reduce these reactions. Most protocols start patients at 0.25mg weekly for a month before increasing, precisely because jumping doses or restarting after a break dramatically increases GI severity. There is also no clinical evidence that pushing through severe side effects speeds up weight outcomes. It just increases your risk of hospitalization. A 2022 analysis in Obesity by Rubino et al. confirmed that slower titration significantly reduced discontinuation due to GI events without sacrificing efficacy. Suffering through it is not the strategy.

  • Contact your prescriber if vomiting lasts beyond 24-48 hours after injection.
  • Do not skip the titration phase. Lower starting doses exist for a reason.
  • Dehydration from prolonged vomiting can require IV fluids and medical intervention.
  • Restarting semaglutide after a break may require stepping back down in dose.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Anessa behind the block · TikTok creator

40.4K views on this video

Ozempic #arkansas #f #sick

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about vomiting?

Vomiting is reported in up to 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM), making it the most common reason for dose reduction or discontinuation.

What does the video say about multi-day vomiting without food intake?

Multi-day vomiting without food intake is a medical situation. Dehydration and electrolyte imbalance can develop quickly and may require IV fluids or emergency evaluation.

What does the video say about slower titration dramatically reduces severe gi side effects. standard protocols?

Slower titration dramatically reduces severe GI side effects. Standard protocols begin at 0.25mg weekly for four weeks before any increase. Rubino et al. (2022, Obesity) confirmed this reduces discontinuation without sacrificing weight outcomes.

What does the video say about restarting semaglutide after stopping, even briefly, typically requires stepping the?

Restarting semaglutide after stopping, even briefly, typically requires stepping the dose back down. Jumping back to a prior dose after a gap significantly increases GI reaction severity.

What does the video say about sodhi et al. (2023, jama internal medicine) found glp-1 receptor?

Sodhi et al. (2023, JAMA Internal Medicine) found GLP-1 receptor agonists associated with higher rates of gastroparesis and bowel obstruction compared to other weight-loss medications, particularly outside supervised clinical settings.

What does the video say about semaglutide sold as ozempic?

Semaglutide sold as Ozempic is FDA-approved for type 2 diabetes management. Wegovy carries the FDA approval for chronic weight management. Using either without a licensed prescriber and proper monitoring removes the safety infrastructure the drug's approval was built around.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Anessa behind the block, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.